The performance of the 14 largest cannabis, psychedelic and plant-based food stocks (those having market capitalizations of at least $400M, and trading for at least $1/share) in 2022 were just horrible, DOWN 70.5%.  After such a massive decline, the market could well offer high returns for investors in 2023 and beyond and, to that end, I have created a basket of those 14 stocks - aptly named the Rags-to-Riches Portfolio - for 2023.

Below are how the various portfolio categories and constituents therein have performed year-to-date:

1. American Cannabis MSO constituents:
   • Cresco (CRLBF): No change YTD,
   • Curaleaf (CURLF): DOWN 6.1% YTD,
   • Green Thumb (GTBIF): UP 1.1% YTD,
   • TerrAscend (TRSSF): UP 54.5 % YTD,
   • Trulieve (TCNNF): DOWN 18.0% YTD, and
   • Verano (VRNOF): DOWN 3.2% YTD.
     • In total: UP 3.9% YTD
   • For comparison purposes, the AdvisorShares Pure U.S. Cannabis ETF (MSOS) is DOWN 5.2% YTD
2. Canadian Cannabis LP constituents:
   • Canopy Growth (CGC): UP 2.6% YTD,
   • Cronos (CRON): DOWN 16.7% YTD, and
   • Tilray (TLRY): UP 5.7% YTD.
     • In total: DOWN 2.8% YTD
   • For comparison purposes, the Global X Cannabis ETF (POTX) is DOWN 4.0% YTD
3. Psychedelic Drug Stock constituents:
   • Atai (ATAI): DOWN 37.2% YTD,
   • Compass Pathways (CMPS): UP 4.6% YTD, and
   • GH Research (GHRS): UP 1.0% YTD.
     • In total: UP 3.5% YTD
   • For comparison purposes, the AdvisorShares Psychedelics ETF (PSIL) is DOWN 5.0% YTD
4. Plant-Based Food Stock constituents:
   • Beyond Meat (BYND): UP 53.6% YTD, and
   • Oatly Group (OTLY): UP 22.4% YTD.
     • In total: UP 49.8% YTD
   • No comparable plant-based food stock ETFs

The "Rags-to-Riches" Portfolio is UP 7.5% YTD compared to the S&P 500, which is only UP 3.4% YTD.

The munKNEE "Rags-to-Riches" Portfolio continues to underperform our munKNEE "Multi-bagger" Portfolio, which is UP 15.4% YTD.

More By This Author:

Of The 6 Largest Psychedelic Drug Stocks, Only One Has Not Advanced YTD
Only 2 Of 5 Cannabis Categories Have Advanced YTD
4 Of 5 Largest Canadian Cannabis LPs Have More Than A 50% Likelihood Of Going Bust